![](https://endpts.com/wp-content/uploads/2023/03/Jean-Paul-Kress-MorphoSys-tile.jpg)
Jean-Paul Kress, MorphoSys CEO
MorphoSys chops back again, this time cutting preclinical efforts in late-stage push
Almost exactly a year after MorphoSys $MOR signaled a retreat out of the early-stage programs picked up in its $1.7 billion Constellation buyout and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.